870 micron Imaging of a Transitional Disk in Upper Scorpius: Holdover from the Era of Giant Planet Formation?

We present 880 micron images of the transition disk around the star [PZ99] J160421.7-213028, a solar-mass star in the nearby Upper Scorpius association. With a resolution down to 0.34 arcsec, we resolve the inner hole in this disk, and via model fitting to the visibilities and spectral energy distribution we determine both the structure of the outer region and the presence of sparse dust within the cavity. The disk contains about 0.1 Jupiter masses of mm-emitting grains, with an inner disk edge of about 70 AU. The inner cavity contains a small amount of dust with a depleted surface density in a region extending from about 20-70 AU. Taking into account prior observations indicating little to no stellar accretion, the lack of a binary companion, and the presence of dust near 0.1 AU, we determine that the most likely mechanism for the formation of this inner hole is the presence of one or more giant planets.Comment: 12 pages, 7 figures. To appear in the Astrophysical Journa

A Herschel PACS survey of the dust and gas in Upper Scorpius disks

We present results of far-infrared photometric observations with Herschel PACS of a sample of Upper Scorpius stars, with a detection rate of previously known disk-bearing K and M stars at 70, 100, and 160 micron of 71%, 56%, and 50%, respectively. We fit power-law disk models to the spectral energy distributions of K & M stars with infrared excesses, and have found that while many disks extend in to the sublimation radius, the dust has settled to lower scale heights than in disks of the less evolved Taurus-Auriga population, and have much reduced dust masses. We also conducted Herschel PACS observations for far-infrared line emission and JCMT observations for millimeter CO lines. Among B and A stars, 0 of 5 debris disk hosts exhibit gas line emission, and among K and M stars, only 2 of 14 dusty disk hosts are detected. The OI 63 micron and CII 157 micron lines are detected toward [PZ99] J160421.7-213028 and [PBB2002] J161420.3-190648, which were found in millimeter photometry to host two of the most massive dust disks remaining in the region. Comparison of the OI line emission and 63 micron continuum to that of Taurus sources suggests the emission in the former source is dominated by the disk, while in the other there is a significant contribution from a jet. The low dust masses found by disk modeling and low number of gas line detections suggest that few stars in Upper Scorpius retain sufficient quantities of material for giant planet formation. By the age of Upper Scorpius, giant planet formation is essentially complete.Comment: 48 pages, 14 figures, accepted A&

GM1 Ganglioside Modifies α-Synuclein Toxicity and is Neuroprotective in a Rat α-Synuclein Model of Parkinson\u27s Disease.

While GM1 may interact with α-synuclein in vitro to inhibit aggregation, the ability of GM1 to protect against α-synuclein toxicity in vivo has not been investigated. We used targeted adeno-associated viral vector (AAV) overexpression of human mutant α-synuclein (A53T) in the rat substantia nigra (SN) to produce degeneration of SN dopamine neurons, loss of striatal dopamine levels, and behavioral impairment. Some animals received daily GM1 ganglioside administration for 6 weeks, beginning 24 hours after AAV-A53T administration or delayed start GM1 administration for 5 weeks beginning 3 weeks after AAV-A53T administration. Both types of GM1 administration protected against loss of SN dopamine neurons and striatal dopamine levels, reduced α-synuclein aggregation, and delayed start administration of GM1 reversed early appearing behavioral deficits. These results extend prior positive results in MPTP models, are consistent with the results of a small clinical study of GM1 in PD patients that showed slowing of symptom progression with chronic use, and argue for the continued refinement and development of GM1 as a potential disease modifying therapy for PD

Quantum interferometric optical lithography:towards arbitrary two-dimensional patterns

As demonstrated by Boto et al. [Phys. Rev. Lett. 85, 2733 (2000)], quantum lithography offers an increase in resolution below the diffraction limit. Here, we generalize this procedure in order to create patterns in one and two dimensions. This renders quantum lithography a potentially useful tool in nanotechnology.Comment: 9 pages, 5 figures Revte

The Masses of Transition Circumstellar Disks: Observational Support for Photoevaporation Models

We report deep Sub-Millimeter Array observations of 26 pre-main-sequence (PMS) stars with evolved inner disks. These observations measure the mass of the outer disk (r ~20-100 AU) across every stage of the dissipation of the inner disk (r < 10 AU) as determined by the IR spectral energy distributions (SEDs). We find that only targets with high mid-IR excesses are detected and have disk masses in the 1-5 M_Jup range, while most of our objects remain undetected to sensitivity levels of M_DISK ~0.2-1.5 M_Jup. To put these results in a more general context, we collected publicly available data to construct the optical to millimeter wavelength SEDs of over 120 additional PMS stars. We find that the near-IR and mid-IR emission remain optically thick in objects whose disk masses span 2 orders of magnitude (~0.5-50 M_Jup). Taken together, these results imply that, in general, inner disks start to dissipate only after the outer disk has been significantly depleted of mass. This provides strong support for photoevaporation being one of the dominant processes driving disk evolution.Comment: Accepted for publication by ApJL, 4 pages and 3 figure

Why Do People Undergo THR and What Do They Expect to Gain—A Comparison of the Views of Patients and Health Care Professionals

Little concerted effort has been made to understand why individuals undergo total hip replacement (THR) surgery and their rehabilitation goals. Similarly, insight of views and perspective of health care professionals’ (HCPs) regarding surgery and what objective measures help them with decision-making is lacking. This patient and public involvement report aimed to explore both patients’ and HCPs’ perspectives of THR surgery. Twenty patients, 10 pre-THR, 10 post-THR, 9 physiotherapists, and 6 surgeons took part. Results suggest a consensus among patients and HCPs on pain reduction being the main reason for undergoing THR. The inability to carry out simple daily activities such as dog walking and sleep deprivation had a significant effect on patients’ mental and physical well-being. This article is the first to explore the views of THR patients and HCPs on reasons behind THR surgery amalgamated into a single report. As walking is important, wearable activity monitors are suggested as a possible motivator to enhance patient compliance to self-care rehabilitation and increase quality of life. A future research project on the use of such wearable activity monitors in enhancing mobility post-THR is therefore planned

Evaluating hormonal mechanisms of vitamin D receptor agonist therapy in diabetic kidney disease: the VALIDATE-D study

Background: Insufficient vitamin D status and increased renin-angiotensin system (RAS) activity have been associated with renal-vascular disease and nephropathy in diabetes. Accumulating evidence indicates that vitamin D receptor (VDR) activation lowers unfavorable RAS activity; however, more human intervention studies evaluating whether this mechanism could influence diabetic kidney disease are needed. We previously reported that both vitamin D levels and genetic variation at the VDR predict human RAS activity, and that vitamin D therapy can lower RAS activity in non-diabetics. The VALIDATE-D study is a randomized, placebo-controlled, intervention study designed to extend these findings by evaluating whether direct VDR activation in diabetes lowers circulating and local renal-vascular tissue RAS activity (Aims 1 and 2) in a manner similar to the action of ACE inhibitors (Aim 3). Methods/Design Forty subjects with type 2 diabetes, microalbuminuria, and without chronic kidney disease will be recruited to undergo detailed assessment of the RAS before and after randomization to calcitriol 0.75 mcg/day or placebo. Primary analyses will evaluate whether calcitriol therapy reduces circulating and renal-vascular tissue-RAS activity in comparison to placebo. All subjects will thereafter be treated with lisinopril and followed for 3.5 months to evaluate whether combination therapy (calcitriol + lisinopril vs. placebo + lisinopril) additively or synergistically improves renal-vascular function, and lowers proteinuria. Discussion The VALIDATE-D study is the first human intervention study to evaluate whether direct VDR activation can lower the human RAS in diabetes, compared to the effect of an ACE inhibitor, and whether this mechanism can translate to clinically relevant endpoints for diabetic kidney disease. The outcomes of VALIDATE-D will have major implications for the recommendation of vitamin D supplementation for the primary prevention of kidney complications in diabetes. Trial registration ClinicalTrials.gov, NCT0163506